Market Research International

New Report: Global Hyperphosphatemia Drugs Market 2015-2019

Press Release   •   Aug 31, 2015 02:16 EDT

About hyperphosphatemia
Phosphorus is an important element for normal physiologic functions such as bone construction, nerve function, and muscle contraction. About 85% of phosphorus is stored in the bones and different tissues in the body. The excess phosphorus is eliminated from the body by the urinary system. The normal phosphate level in the blood is 3-4 mg/dL. Electrolytic disturbance resulting in high levels of phosphate in the blood causes hyperphosphatemia. Individuals with chronic kidney diseases have a decreased glomerular filtration rate and increased serum phosphate levels. The high phosphate levels in the serum lower calcium levels because of phosphate precipitation by calcium ions, leading to calcification of vascular tissues and heart diseases. Aluminum-, calcium-, magnesium-, and iron-based and aluminum-free, calcium-free phosphate binders are used to treat the condition.

The report's analysts forecast the global hyperphosphatemia drugs market to grow at a CAGR of 10.71% over the period 2014-2019.

Covered in this Report
In this report, we cover the present scenario and growth prospects of the global hyperphosphatemia drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of branded, generic, OTC, and off-label drugs used for treating hyperphosphatemia.

This report, Global Hyperphosphatemia Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global hyperphosphatemia drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions
- Americas
- APAC
- EMEA

Key vendors
- Fresenius Medical Care
- Keryx Biopharmaceuticals
- Sanofi
- Shire
- Vifor Pharma

Other prominent vendors
- Alkem
- Amgen
- Ardelyx
- AstraZeneca
- Baxter
- Bayer
- Chugai Pharmaceutical
- Japan Tobacco
- Kissei Pharmaceutical
- Kyowa Hakko Kirin
- Mylan
- Natco
- Novartis
- Opko Health
- Panion & BF Biotech
- Roxane Laboratories
- Sandoz
- Synthon
- Torri Pharmaceutical

Market driver
- Increased number of people undergoing dialysis
- For a full, detailed list, view our report

Market challenge
- Non-adherence to treatment regimens
- For a full, detailed list, view our report

Market trend
- Patient assistance programs
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

thttp://www.marketresearchint.com/medical-devices-market-research-reports/global-hyperphosphatemia-drugs-market-2015-2019.html

Market Research International is a leading distributor of PREMIUM market research reports.